Widely used:Recently Viewed
Clear AllQuality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$199 Mln
P/E Ratio
--
P/B Ratio
4.25
Industry P/E
--
Debt to Equity
0.01
ROE
-0.53 %
ROCE
-52.84 %
Div. Yield
0 %
Book Value
1.02
EPS
-0.61
CFO
$-78.52 Mln
EBITDA
$-90.27 Mln
Net Profit
$-88.07 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
DiaMedica Therapeutics (DMAC)
| -21.18 | 12.04 | -28.07 | 66.54 | 23.36 | 2.52 | -- |
|
BSE Sensex
| 2.61 | 3.71 | 5.78 | 8.89 | 11.76 | 20.11 | 11.35 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2023
|
2022
|
2021
|
2020
|
2019
|
|
|---|---|---|---|---|---|
|
DiaMedica Therapeutics (DMAC)
| 79.74 | -57.64 | -63.21 | 109.07 | 66.67 |
|
S&P Small-Cap 600
| 13.89 | -17.42 | 25.27 | 9.57 | 20.86 |
|
BSE Sensex
| 18.74 | 4.44 | 21.99 | 15.75 | 14.38 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 2.55 | 771.79 | -- | -14.75 | |
| 8.12 | 1,093.17 | 200 | 1.52 | |
| 2.87 | 90.24 | -- | -19.21 | |
| 38.37 | 2,898.30 | -- | -27.85 |
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue... kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company also develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the treatment of inflammatory diseases, such as acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota. Address: 301 Carlson Parkway, Minneapolis, MN, United States, 55305 Read more
President, CEO & Director
Mr. Dietrich John Pauls MBA
President, CEO & Director
Mr. Dietrich John Pauls MBA
Headquarters
Minneapolis, MN
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of DiaMedica Therapeutics Inc (DMAC) stood at $ 46 Mln as on 31-Dec-24
The share price of DiaMedica Therapeutics Inc (DMAC) is $4.28 (NASDAQ) as of 29-Apr-2025 16:00 EDT. DiaMedica Therapeutics Inc (DMAC) has given a return of 23.36% in the last 3 years.
DiaMedica Therapeutics Inc (DMAC) has a market capitalisation of $ 199 Mln as on 29-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of DiaMedica Therapeutics Inc (DMAC) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the DiaMedica Therapeutics Inc (DMAC) and enter the required number of quantities and click on buy to purchase the shares of DiaMedica Therapeutics Inc (DMAC).
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company also develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the treatment of inflammatory diseases, such as acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota. Address: 301 Carlson Parkway, Minneapolis, MN, United States, 55305
The CEO & director of Mr. Dietrich John Pauls MBA. is DiaMedica Therapeutics Inc (DMAC), and CFO & Sr. VP is Mr. Dietrich John Pauls MBA.
There is no promoter pledging in DiaMedica Therapeutics Inc (DMAC).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
328
|
|
|
145
|
|
|
86
|
|
|
22
|
| DiaMedica Therapeutics Inc. (DMAC) | Ratios |
|---|---|
|
Return on equity(%)
|
-53.27
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of DiaMedica Therapeutics Inc (DMAC) was $0 Mln.
$-0.36
(
